In line with this, simultaneous inhibition of EGFR/ERBB2 by the dual targeting inhibitor afatinib is more effective than gefitinib in patients with EGFR mutant NSCLC (68), and afatinib is now the standard first-line therapy in patients with activating EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.